KYMR
Kymera Therapeutics, Inc.
$110.76
-0.08%
2026-10-23
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Key Fundamentals
Forward P/E
-21.95
EPS (TTM)
$-3.25
ROE
-24.2%
Revenue Growth (YoY)
466.4%
Profit Margin
-285.3%
Debt/Equity
5.21
Price/Book
6.14
Beta
1.97
Market Cap
$9.31B
Avg Volume (10D)
833K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$127.85
60D Low
$99.52
Avg Volume
757K
Latest Close
$110.76
Get breakout alerts for KYMR
Sign up for Breakout Scanner to receive daily notifications when KYMR triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Kymera Therapeutics, Inc. (KYMR) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors KYMR daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. KYMR operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.